Wire · opportunities
Teva's TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 September 2026 · Fusion42 review
Teva's TEV-749, a once-monthly subcutaneous olanzapine long-acting injectable, showed an 80% clinical stabilization rate in schizophrenia patients in the Phase 3 SOLARIS trial, with durable effects in the open-label extension. The product's success and adoption will heavily depend on whether regulatory authorities require post-injection monitoring, unlike the existing intramuscular formulation Zyprexa Relprevv.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 18 Sep 2026 and 19 Sep 2026.
◆ ◆ The Wire takeaway
Your schizophrenia drug faces a pivotal moment: the FDA's decision on post-injection monitoring will make or break TEV-749's market edge. Start mapping your regulatory strategy and target clinicians who need a seamless switch from oral to injectable treatments.
◆ Coverage
2 sources · first reported 18 Sep 2026 · latest 19 Sep 2026
◆ Related on Wire
◆ Topics